Medication info
Pregabalin Orally Disintegrating Tablets 150 mg (Pregabalin)

Pregabalin Orally Disintegrating Tablets 150 mg (Pregabalin)

Prescription medicationOrally disintegrating Tablet
Ingredient · strength
Pregabalin›150mg / 1 tablet
Manufacturer / importer
Huons
Appearance
Pink oval orally disintegrating tablet
Packaging
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Approval status
Active

MFDS item code 202600538 · Approved 2026.02.24

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Place it on the tongue and, once it has disintegrated, swallow it without water. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
7. Pediatric and adolescent patients Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Huons

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in patients with epilepsy, with or without secondary generalized symptoms. It is effective in improving symptoms in patients with fibromyalgia. Thus, it contributes to enhancing the quality of life for patients suffering from neuropathic pain, epilepsy, and fibromyalgia.

Dosage and Administration

Adult dosage

This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Place it on the tongue and, once it has disintegrated, swallow it without water. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

7. Pediatric and adolescent patients Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; if mood changes or unusual behaviors occur during treatment, it is crucial to inform healthcare professionals immediately. This medication should not be used if there is a history of allergic reactions to it or its components. Diabetic patients may need to adjust their blood sugar control medications due to weight gain from taking this medication, so caution is advised. If swelling occurs in the face or around the mouth, discontinue use immediately and consult a healthcare professional. Elderly patients are at risk of dizziness and drowsiness, increasing the risk of falls, so caution is required, especially at the beginning of treatment. Visual disturbances or changes in eyesight can occur, so these symptoms should be reported to healthcare professionals. Abrupt cessation of this medication can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off under medical supervision. Due to the risk of drug abuse, patients with a history of substance abuse should exercise special caution when taking this medication. Patients with impaired kidney function may require dosage adjustments. Patients with cardiac diseases should use this medication cautiously due to the risk of congestive heart failure. There is a central nervous system depressant effect, which can lead to drowsiness, stupor, and respiratory depression; therefore, caution is necessary when used in combination with opioids or similar medications. During early pregnancy, there is a risk of fetal malformations, so pregnant women should avoid taking this medication, and women of childbearing age should use effective contraception during treatment. Breastfeeding women should discuss with their healthcare provider regarding the continuation of breastfeeding or the discontinuation of this medication, as it can be transmitted through breast milk. It is advisable to avoid hazardous activities such as driving or operating machinery until dizziness or drowsiness resolves after taking this medication. If severe skin reactions such as rashes, fever, or mucosal damage occur during treatment, discontinue use immediately and inform healthcare professionals. Overdosage may result in symptoms like confusion, drowsiness, and depression; seek emergency treatment if suspected. Keep this medication out of reach of children, and avoid transferring it to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • periorbital edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 185 more
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual dysesthesia
  • restlessness
  • mood swings
  • emotional low
  • emotional highs
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to restrain
  • apathy
  • ataxia
  • motor coordination impairment
  • balance disorder
  • memory loss
  • attention deficit
  • memory deficit
  • tremor
  • dysarthria
  • sensory abnormalities
  • sensory suppression
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • speech disorder
  • myoclonus
  • reflex suppression
  • abnormal movements
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • bradycardia
  • intrinsic tachycardia
  • intrinsic arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • abdominal bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • vesicular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • diminished urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • abnormal gait
  • falls
  • feeling intoxicated
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased potassium in the blood
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • worsening of convulsions
  • fatigue
  • weakness
  • abnormal gait
  • sleep disorder
  • ataxia
  • dysphonia
  • blood in stool
  • increased BUN
  • urinary difficulties
  • tinnitus
  • skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. The recommended storage temperature is between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

Pink oval orally disintegrating tablet

Package unit

30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.